Similarly, the NICE recommends prioritizing them to subjects with BMI ≥35 kg/m2 and obesity-related medical problems and, also, to those non-obese for whom weight loss is desirable to prevent obesity-related comorbidities or for whom insulin therapy is not appropriate because of occupational repercussions [21]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.